{
    "clinical_study": {
        "@rank": "14894", 
        "acronym": "CIK", 
        "brief_summary": {
            "textblock": "To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in\n      refractory and/or chemoresistant lymphomas."
        }, 
        "brief_title": "Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphomas", 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "Autologous CIK transfusion within 3 days post CD20 antibody treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy\n\n        Exclusion Criteria:\n\n        - to refuse the therapy and need not tolerate the therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "the patients with CD20-positive Lymphomas"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828008", 
            "org_study_id": "BT-004"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mabthera", 
            "cytokine induced killer cell"
        ], 
        "lastchanged_date": "April 9, 2013", 
        "number_of_groups": "1", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: General Hospital of PLA", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "disease free survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828008"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Han weidong", 
            "investigator_title": "combination of anti-CD20 with CIK for refractory lymphomas", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Han weidong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "January 2013"
    }
}